LATEST UPDATES » Vol 24, No. 08, August 2020 – Unravelling the Mysteries of the Human Brain       » Reducing Blood Sugar with Tea Leaves in Type 2 Diabetic Rats       » Generating Clean Water from Solar-Powered Technology       » COVID-19 Diagnostic Kits: The Singapore Story       » Fighting for Sustainability: One Shrimp at a Time       » Creating Robotic Systems with Vision and Touch Sensors      
Vol 23, No. 07, July 2019   |   Issue PDF view/purchase
Digital mental health strategy in China
Holmusk signs Memorandum of Understanding with Janssen (China) Research & Development Center to develop digital mental health strategy in China

Holmusk has signed a Memorandum of Understanding (MoU) with Janssen (China) Research & Development Center (Janssen), a Division of Johnson & Johnson (China) Investment Ltd., to explore the development of a digital mental health strategy in China.

The MoU brings together Janssen’s 60-plus years of experience developing treatments to improve mental health and its China neuroscience portfolio with Holmusk’s digital mental health platform and therapeutics design expertise to develop integrated solutions to help people living with depression and other mental health disorders.

More than 54 million people in China (4.2% of the population) suffer from depression. Proper diagnosis and treatment for depression is rare, especially in underserved regions, with less than 2 out of 10 patients seeking medical help or taking medications. Stigma regarding mental health remains high, preventing many patients from seeking care, and China has only 1.7 psychiatrists for every 100,000 people.

While depression costs China USD 7.8 billion a year in lost work days, medical expenses and funeral expenses, there is a lack of available, credible data on both prevalence and treatment.

Holmusk and Janssen propose to focus on generating insights from real-world data on depression and other mental health disorders to develop novel, scalable solutions to address the increasing burden of disease in the People’s Republic of China. The parties would also identify areas of unmet need that a digital platform can enhance, and define the supporting, prioritized functionality based on the Janssen Neuroscience portfolio in China. Holmusk’s digital therapeutics and deep analytics will be used to develop and implement a competitive, comprehensive solution for mental health in China, with an initial focus on depression.

Holmusk will work with Janssen to develop a strategy that applies Holmusk’s digital therapeutics capabilities and deep mental health analytics expertise to leverage big data and real-world evidence for a broad spectrum of mental health challenges. The combination of Holmusk’s mental health platform and Janssen’s expertise and network will be used to inform future, targeted management of wellness-oriented consumers, as well as mental health patients.

Source: Holmusk

news Singapore Biomedical Company Appointed as a Certified Service Provider by 10x Genomics
news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Grou
news Twist Bioscience and Proteona Join Hands to Protect Immunocompromised Patients from COVID-19 Infection
news Meeting Demand for Respiratory Ventilators Amid COVID-19 Pandemic

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy